| Dr Adrienne Cain, CRNA | |
|
4320 Seminary Rd, Alexandria, VA 22304-1535 | |
| (703) 504-3000 | |
| Not Available |
| Full Name | Dr Adrienne Cain |
|---|---|
| Gender | Female |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 6 Years |
| Location | 4320 Seminary Rd, Alexandria, Virginia |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1629425368 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | 22649558 (New York) | Secondary |
| 367500000X | Nurse Anesthetist, Certified Registered | R231758 (Maryland) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| First Colonies Anesthesia Associates, Llc | 8426039744 | 359 |
| First Colonies Anesthesia Associates, Llc | 8426039744 | 359 |
| Zephyr Anesthesia Llc | 1658559125 | 130 |
News Archive
Hospital characteristics, including size, non-profit status and affiliation with a university, appear to be associated with use of do-not-resuscitate orders (DNR) in California, independent of the patient's characteristics, according to a study in the August 8/22 issue of Archives of Internal Medicine.
Scientists have discovered for the first time a specific biochemical pathway by which the sex hormone, androgen, increases levels of harmful chemicals called reactive oxygen species (ROS) in the prostate gland that play a role in the development of prostate cancer.
The government, the NHS, and employers are failing to provide the necessary support for people with chronic MSDs (musculoskeletal disorders) to stay in work. This is according to a new report released today (Friday 5th September) by Lancaster University's Work Foundation and the Fit for Work UK Coalition.
CyDex Pharmaceuticals, Inc. today announced a mutual decision with Prism Pharmaceuticals to terminate their existing joint development agreement on novel Captisol-enabled® intravenous formulations of clopidogrel. This provides CyDex with full development and commercialization rights to the product candidate - an injectable formulation of clopidogrel. Clopidogrel is the active ingredient in PLAVIX®, an orally available antiplatelet drug, which currently is marketed by Bristol-Myers Squibb Company and Sanofi-Aventis, Inc.
› Verified 7 days ago
| Entity Name | Johns Hopkins University |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922008549 PECOS PAC ID: 8921903147 Enrollment ID: O20031215000719 |
News Archive
Hospital characteristics, including size, non-profit status and affiliation with a university, appear to be associated with use of do-not-resuscitate orders (DNR) in California, independent of the patient's characteristics, according to a study in the August 8/22 issue of Archives of Internal Medicine.
Scientists have discovered for the first time a specific biochemical pathway by which the sex hormone, androgen, increases levels of harmful chemicals called reactive oxygen species (ROS) in the prostate gland that play a role in the development of prostate cancer.
The government, the NHS, and employers are failing to provide the necessary support for people with chronic MSDs (musculoskeletal disorders) to stay in work. This is according to a new report released today (Friday 5th September) by Lancaster University's Work Foundation and the Fit for Work UK Coalition.
CyDex Pharmaceuticals, Inc. today announced a mutual decision with Prism Pharmaceuticals to terminate their existing joint development agreement on novel Captisol-enabled® intravenous formulations of clopidogrel. This provides CyDex with full development and commercialization rights to the product candidate - an injectable formulation of clopidogrel. Clopidogrel is the active ingredient in PLAVIX®, an orally available antiplatelet drug, which currently is marketed by Bristol-Myers Squibb Company and Sanofi-Aventis, Inc.
› Verified 7 days ago
| Entity Name | Anesthesia Company Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1871548156 PECOS PAC ID: 4587559026 Enrollment ID: O20040216000401 |
News Archive
Hospital characteristics, including size, non-profit status and affiliation with a university, appear to be associated with use of do-not-resuscitate orders (DNR) in California, independent of the patient's characteristics, according to a study in the August 8/22 issue of Archives of Internal Medicine.
Scientists have discovered for the first time a specific biochemical pathway by which the sex hormone, androgen, increases levels of harmful chemicals called reactive oxygen species (ROS) in the prostate gland that play a role in the development of prostate cancer.
The government, the NHS, and employers are failing to provide the necessary support for people with chronic MSDs (musculoskeletal disorders) to stay in work. This is according to a new report released today (Friday 5th September) by Lancaster University's Work Foundation and the Fit for Work UK Coalition.
CyDex Pharmaceuticals, Inc. today announced a mutual decision with Prism Pharmaceuticals to terminate their existing joint development agreement on novel Captisol-enabled® intravenous formulations of clopidogrel. This provides CyDex with full development and commercialization rights to the product candidate - an injectable formulation of clopidogrel. Clopidogrel is the active ingredient in PLAVIX®, an orally available antiplatelet drug, which currently is marketed by Bristol-Myers Squibb Company and Sanofi-Aventis, Inc.
› Verified 7 days ago
| Entity Name | North American Partners In Anesthesia Maryland Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093707879 PECOS PAC ID: 1850283144 Enrollment ID: O20040330000405 |
News Archive
Hospital characteristics, including size, non-profit status and affiliation with a university, appear to be associated with use of do-not-resuscitate orders (DNR) in California, independent of the patient's characteristics, according to a study in the August 8/22 issue of Archives of Internal Medicine.
Scientists have discovered for the first time a specific biochemical pathway by which the sex hormone, androgen, increases levels of harmful chemicals called reactive oxygen species (ROS) in the prostate gland that play a role in the development of prostate cancer.
The government, the NHS, and employers are failing to provide the necessary support for people with chronic MSDs (musculoskeletal disorders) to stay in work. This is according to a new report released today (Friday 5th September) by Lancaster University's Work Foundation and the Fit for Work UK Coalition.
CyDex Pharmaceuticals, Inc. today announced a mutual decision with Prism Pharmaceuticals to terminate their existing joint development agreement on novel Captisol-enabled® intravenous formulations of clopidogrel. This provides CyDex with full development and commercialization rights to the product candidate - an injectable formulation of clopidogrel. Clopidogrel is the active ingredient in PLAVIX®, an orally available antiplatelet drug, which currently is marketed by Bristol-Myers Squibb Company and Sanofi-Aventis, Inc.
› Verified 7 days ago
| Entity Name | First Colonies Anesthesia Associates, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740218767 PECOS PAC ID: 8426039744 Enrollment ID: O20040525000119 |
News Archive
Hospital characteristics, including size, non-profit status and affiliation with a university, appear to be associated with use of do-not-resuscitate orders (DNR) in California, independent of the patient's characteristics, according to a study in the August 8/22 issue of Archives of Internal Medicine.
Scientists have discovered for the first time a specific biochemical pathway by which the sex hormone, androgen, increases levels of harmful chemicals called reactive oxygen species (ROS) in the prostate gland that play a role in the development of prostate cancer.
The government, the NHS, and employers are failing to provide the necessary support for people with chronic MSDs (musculoskeletal disorders) to stay in work. This is according to a new report released today (Friday 5th September) by Lancaster University's Work Foundation and the Fit for Work UK Coalition.
CyDex Pharmaceuticals, Inc. today announced a mutual decision with Prism Pharmaceuticals to terminate their existing joint development agreement on novel Captisol-enabled® intravenous formulations of clopidogrel. This provides CyDex with full development and commercialization rights to the product candidate - an injectable formulation of clopidogrel. Clopidogrel is the active ingredient in PLAVIX®, an orally available antiplatelet drug, which currently is marketed by Bristol-Myers Squibb Company and Sanofi-Aventis, Inc.
› Verified 7 days ago
| Entity Name | Center For Pain Management, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1962463265 PECOS PAC ID: 0547246555 Enrollment ID: O20040629000496 |
News Archive
Hospital characteristics, including size, non-profit status and affiliation with a university, appear to be associated with use of do-not-resuscitate orders (DNR) in California, independent of the patient's characteristics, according to a study in the August 8/22 issue of Archives of Internal Medicine.
Scientists have discovered for the first time a specific biochemical pathway by which the sex hormone, androgen, increases levels of harmful chemicals called reactive oxygen species (ROS) in the prostate gland that play a role in the development of prostate cancer.
The government, the NHS, and employers are failing to provide the necessary support for people with chronic MSDs (musculoskeletal disorders) to stay in work. This is according to a new report released today (Friday 5th September) by Lancaster University's Work Foundation and the Fit for Work UK Coalition.
CyDex Pharmaceuticals, Inc. today announced a mutual decision with Prism Pharmaceuticals to terminate their existing joint development agreement on novel Captisol-enabled® intravenous formulations of clopidogrel. This provides CyDex with full development and commercialization rights to the product candidate - an injectable formulation of clopidogrel. Clopidogrel is the active ingredient in PLAVIX®, an orally available antiplatelet drug, which currently is marketed by Bristol-Myers Squibb Company and Sanofi-Aventis, Inc.
› Verified 7 days ago
| Entity Name | Physical Medicine Associates Ltd |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003884560 PECOS PAC ID: 4981688835 Enrollment ID: O20190509000017 |
News Archive
Hospital characteristics, including size, non-profit status and affiliation with a university, appear to be associated with use of do-not-resuscitate orders (DNR) in California, independent of the patient's characteristics, according to a study in the August 8/22 issue of Archives of Internal Medicine.
Scientists have discovered for the first time a specific biochemical pathway by which the sex hormone, androgen, increases levels of harmful chemicals called reactive oxygen species (ROS) in the prostate gland that play a role in the development of prostate cancer.
The government, the NHS, and employers are failing to provide the necessary support for people with chronic MSDs (musculoskeletal disorders) to stay in work. This is according to a new report released today (Friday 5th September) by Lancaster University's Work Foundation and the Fit for Work UK Coalition.
CyDex Pharmaceuticals, Inc. today announced a mutual decision with Prism Pharmaceuticals to terminate their existing joint development agreement on novel Captisol-enabled® intravenous formulations of clopidogrel. This provides CyDex with full development and commercialization rights to the product candidate - an injectable formulation of clopidogrel. Clopidogrel is the active ingredient in PLAVIX®, an orally available antiplatelet drug, which currently is marketed by Bristol-Myers Squibb Company and Sanofi-Aventis, Inc.
› Verified 7 days ago
| Entity Name | Cainesthesia Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154033033 PECOS PAC ID: 2860866597 Enrollment ID: O20230321001435 |
News Archive
Hospital characteristics, including size, non-profit status and affiliation with a university, appear to be associated with use of do-not-resuscitate orders (DNR) in California, independent of the patient's characteristics, according to a study in the August 8/22 issue of Archives of Internal Medicine.
Scientists have discovered for the first time a specific biochemical pathway by which the sex hormone, androgen, increases levels of harmful chemicals called reactive oxygen species (ROS) in the prostate gland that play a role in the development of prostate cancer.
The government, the NHS, and employers are failing to provide the necessary support for people with chronic MSDs (musculoskeletal disorders) to stay in work. This is according to a new report released today (Friday 5th September) by Lancaster University's Work Foundation and the Fit for Work UK Coalition.
CyDex Pharmaceuticals, Inc. today announced a mutual decision with Prism Pharmaceuticals to terminate their existing joint development agreement on novel Captisol-enabled® intravenous formulations of clopidogrel. This provides CyDex with full development and commercialization rights to the product candidate - an injectable formulation of clopidogrel. Clopidogrel is the active ingredient in PLAVIX®, an orally available antiplatelet drug, which currently is marketed by Bristol-Myers Squibb Company and Sanofi-Aventis, Inc.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Adrienne Cain, CRNA Po Box 27058, Baltimore, MD 21230-0058 Ph: () - | Dr Adrienne Cain, CRNA 4320 Seminary Rd, Alexandria, VA 22304-1535 Ph: (703) 504-3000 |
News Archive
Hospital characteristics, including size, non-profit status and affiliation with a university, appear to be associated with use of do-not-resuscitate orders (DNR) in California, independent of the patient's characteristics, according to a study in the August 8/22 issue of Archives of Internal Medicine.
Scientists have discovered for the first time a specific biochemical pathway by which the sex hormone, androgen, increases levels of harmful chemicals called reactive oxygen species (ROS) in the prostate gland that play a role in the development of prostate cancer.
The government, the NHS, and employers are failing to provide the necessary support for people with chronic MSDs (musculoskeletal disorders) to stay in work. This is according to a new report released today (Friday 5th September) by Lancaster University's Work Foundation and the Fit for Work UK Coalition.
CyDex Pharmaceuticals, Inc. today announced a mutual decision with Prism Pharmaceuticals to terminate their existing joint development agreement on novel Captisol-enabled® intravenous formulations of clopidogrel. This provides CyDex with full development and commercialization rights to the product candidate - an injectable formulation of clopidogrel. Clopidogrel is the active ingredient in PLAVIX®, an orally available antiplatelet drug, which currently is marketed by Bristol-Myers Squibb Company and Sanofi-Aventis, Inc.
› Verified 7 days ago
Mr. Valentine Jean Toussaint Niles, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 4320 Seminary Rd, Alexandria, VA 22304 Phone: 703-504-3521 | |
Stephen C Winfrey, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 6355 Walker Ln, 200, Alexandria, VA 22310 Phone: 703-922-9501 Fax: 703-922-5347 | |
David Trowbridge, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 4320 Seminary Rd, Alexandria, VA 22304 Phone: 703-504-3789 Fax: 703-504-3556 | |
Mrs. Judith R Williams, CRNA Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 4320 Seminary Rd, Alexandria, VA 22304 Phone: 703-766-9697 | |
Ms. Mary Jane Kearney, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 2501 Parkers Ln, Alexandria, VA 22306 Phone: 703-295-9360 | |
Anna Morgan, Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 2501 Parkers Ln, Alexandria, VA 22306 Phone: 703-664-7000 | |
Mr. Mychael Dennis Mendoza, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 4320 Seminary Rd, Alexandria, VA 22304 Phone: 703-766-9699 |